CSR02-Fab-TF
Hepatocellular Carcinoma
Koo Foundation Sun Yat-Sen Cancer CenterEarly Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 73/ 100
Competitive context
520 Active assets in the Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adefovir Bukwang Pharmaceutical | Phase 4 | BBB |
Huaier Granule Tongji Hospital | Phase 4 | BBB |
Theprubicin RWTH Aachen University | Phase 4 | BB |
nrt6003 Second Affiliated Hospital of Guangzhou Medical University | Phase 3 | BB |
Inno-206 VA Office of Research and Development | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →